OPKO subsidiary ModeX awarded $59M BARDA contract for multispecific antibody against SARS-CoV-2, up to $168M total

OPKO HEALTH, INC.

ModeX (OPKO subsidiary) received initial $59M from BARDA for MSTAR multispecific antibody Phase 1 trial against SARS-CoV-2.
Up to $109M additional contingent on milestones for developing antibodies against influenza and other viral pathogens.
Total potential contract value $168M; part of HHS' Project NextGen for innovative COVID-19 vaccines and therapeutics.
Gene-based delivery methods (mRNA/DNA vectors) will be developed to leverage body's natural protein production.
In March 2023, ModeX entered exclusive worldwide license with Merck for Epstein-Barr virus vaccine candidate MDX2201.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.